A pair of drugmakers priced their initial public offerings on Thursday, delivering the best month for US health care ...

Study reveals the impact of X chromosome on brain aging in women. Learn how maternal and paternal X chromosome can influence ...

A hunt for mountain lions along the Gila River in New Mexico led the hunter, Charles Elliott, and his guide on a chase ...

Capital Breakfast's Jordan North, Chris Stark & Sian Welby paid a visit to the haunted London Tombs to try out their ...

Maze Therapeutics became the latest drug developer to list in New York on Friday, with its shares rising nearly 1% in their debut, giving the company a valuation of $690.37 million.

Catch The Office, The Traitors, Twisted Metal, NFL, Premier League, college hoops, WWE premium live events, and blockbuster ...

Seven years ago, researchers caught an unexpected phenomenon on film: A pool of red dye that somehow 'knew' how to solve a maze filled with milk. Propelled forward by a couple drops of soap, it ...

Obesity biotech Metsera and renal and metabolic-focused Maze Therapeutics have met their IPO expectations as the two companies prepare to join the Nasdaq this morning. | Obesity biotech Metsera and ...

Until this year, the Guinness World Record was held by a nearly 13,000-square-foot ice labyrinth in New York that took the ...

Available in Titanium and Terracotta Quartz TPT colour, this labyrinthine timepiece boasts a wealth of technical ...

Maze Therapeutics ( NASDAQ: MAZE) shares were trading largely flat following a $140M initial public offering. Shares of the kidney disease drug developer opened at $16 per share after being priced at ...

Those looking for a fun time while learning about the elements of STEAM (Science, Technology, Engineering, Art and Math) had ...